Publications by authors named "David Bingaman"

Claim this Profile
C
Can Sustained Suppression of VEGF Be Achieved by Topical Ocular Delivery?
David Bingaman, Tejaswini Appidi, Jahnavi Pejavar, Laura M Ensign

Am J Ophthalmol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition.
Jamie S Rush, David P Bingaman, Paul G Chaney, Martin B Wax, Brian P Ceresa

Invest Ophthalmol Vis Sci· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of nepafenac and amfenac on retinal angiogenesis.
Susan E Yanni, Monika L Clark, Rong Yang, David P Bingaman, John S Penn

Brain Res Bull· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR.
Joshua M Barnett, Gary W McCollum, Jessica A Fowler, James J-W Duan, Jesse D Kay, David P Bingaman

Invest Ophthalmol Vis Sci· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.
Timothy S Kern, Casey M Miller, Yunpeng Du, Ling Zheng, Susanne Mohr, David P Bingaman

Diabetes· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical nepafenac inhibits ocular neovascularization.
Kyoichi Takahashi, Yoshitsugu Saishin, Yumiko Saishin, Keisuke Mori, Akira Ando, David P Bingaman

Invest Ophthalmol Vis Sci· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis